Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

183 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Serum soluble interleukin-2 receptor predicts early remission in patients with recent-onset rheumatoid arthritis treated with a single disease-modifying antirheumatic drug.
Kuuliala A, Leirisalo-Repo M, Möttönen T, Hannonen P, Nissilä M, Kautiainen H, Korpela M, Julkunen H, Hakola M, Repo H; FIN-RACo Trial Group. Kuuliala A, et al. Among authors: hannonen p. Clin Exp Rheumatol. 2005 Mar-Apr;23(2):243-6. Clin Exp Rheumatol. 2005. PMID: 15895898 Clinical Trial.
Intra-articular glucocorticoid injections should not be neglected in the remission targeted treatment of early rheumatoid arthritis: a post hoc analysis from the NEO-RACo trial.
Kuusalo LA, Puolakka KT, Kautiainen H, Alasaarela EM, Hannonen PJ, Julkunen HA, Kaipiainen-Seppänen OA, Korpela MM, Möttönen TT, Paimela LH, Peltomaa RL, Yli-Kerttula TK, Leirisalo-Repo M, Rantalaiho VM; NEO-RACo Study Group. Kuusalo LA, et al. Clin Exp Rheumatol. 2016 Nov-Dec;34(6):1038-1044. Epub 2016 Aug 2. Clin Exp Rheumatol. 2016. PMID: 27494516 Clinical Trial.
Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.
Möttönen T, Hannonen P, Korpela M, Nissilä M, Kautiainen H, Ilonen J, Laasonen L, Kaipiainen-Seppänen O, Franzen P, Helve T, Koski J, Gripenberg-Gahmberg M, Myllykangas-Luosujärvi R, Leirisalo-Repo M; FIN-RACo Trial Group. FINnish Rheumatoid Arthritis Combination therapy. Möttönen T, et al. Among authors: hannonen p. Arthritis Rheum. 2002 Apr;46(4):894-8. doi: 10.1002/art.10135. Arthritis Rheum. 2002. PMID: 11953964 Free article. Clinical Trial.
Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study.
Korpela M, Laasonen L, Hannonen P, Kautiainen H, Leirisalo-Repo M, Hakala M, Paimela L, Blåfield H, Puolakka K, Möttönen T; FIN-RACo Trial Group. Korpela M, et al. Among authors: hannonen p. Arthritis Rheum. 2004 Jul;50(7):2072-81. doi: 10.1002/art.20351. Arthritis Rheum. 2004. PMID: 15248204 Free article. Clinical Trial.
Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial.
Puolakka K, Kautiainen H, Möttönen T, Hannonen P, Korpela M, Hakala M, Järvinen P, Ahonen J, Forsberg S, Leirisalo-Repo M; FIN-RACo Trial Group. Puolakka K, et al. Among authors: hannonen p. Arthritis Rheum. 2005 Jan;52(1):36-41. doi: 10.1002/art.20716. Arthritis Rheum. 2005. PMID: 15641055 Free article. Clinical Trial.
Prognosis of 5-year radiographic erosions of the wrist according to early, late, and persistent wrist swelling or tenderness in patients with early rheumatoid arthritis.
Luukkainen R, Sokka T, Kautiainen H, Hannonen P, Laasonen L, Leirisalo-Repo M, Korpela M, Julkunen H, Puolakka K, Blåfield H, Kauppi M, Möttönen T; FIN-RACo Trial Group. Luukkainen R, et al. Among authors: hannonen p. J Rheumatol. 2007 Jan;34(1):50-3. J Rheumatol. 2007. PMID: 17216677
183 results